Wu J, Zheng Y, Zhang LN, Gu CL, Chen WL, Chang MQ. Advanced nanomedicines and immunotherapeutics to treat respiratory diseases especially COVID-19 induced thrombosis. World J Clin Cases 2024; 12(16): 2704-2712 [PMID: 38899301 DOI: 10.12998/wjcc.v12.i16.2704]
Corresponding Author of This Article
Min-Qiang Chang, MD, PhD, Chief Physician, Department of Otorhinolaryngology, 72nd Group Army Hospital of PLA, Chezhan Road, Wuxing District, Huzhou 313000, Zhejiang Province, China. cmqent98@163.com
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jie Wu, Ying Zheng, Li-Na Zhang, Cai-Li Gu, Wang-Li Chen, Department of Respiratory and Oncology, 72nd Group Army Hospital of PLA, Huzhou 313000, Zhejiang Province, China
Min-Qiang Chang, Department of Otorhinolaryngology, 72nd Group Army Hospital of PLA, Huzhou 313000, Zhejiang Province, China
Author contributions: Wu J, Chang MQ, contributed to the design of the study, collected data and drafted the manuscript; Wu J, Zhang LN, Gu CL performed the data analyses and revised the manuscript; Chen WL, Chang MQ, Zheng Y helped perform the analysis with constructive discussions; Chang MQ conceived the work that led to the submission and approved the final version; and all authors issued final approval for the version to be submitted.
Conflict-of-interest statement: All authors have no conflicts of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Min-Qiang Chang, MD, PhD, Chief Physician, Department of Otorhinolaryngology, 72nd Group Army Hospital of PLA, Chezhan Road, Wuxing District, Huzhou 313000, Zhejiang Province, China. cmqent98@163.com
Received: December 24, 2023 Revised: March 6, 2024 Accepted: April 16, 2024 Published online: June 6, 2024 Processing time: 157 Days and 8.9 Hours
Core Tip
Core Tip: Respiratory infectious diseases have been known for their leading role in causing of morbidity and mortality, and thus are serious threat to global healthcare systems. Coronavirus disease 2019 (COVID-19) and H1N1 influenza viral diseases, and tuberculosis are respiratory infection disease that have caused huge burden on healthcare system and caused death in millions of people across the globe. Immune system plays critical role to control these infections such that COVID-19 triggers immune responses and activates inflammatory reactions soon after the viral entrance into the body. Meanwhile antiinflammatory responses are generated to decrease the severity of symptoms and proceed for recovery. In this regard researchers have reported unique involvement of NETosis in the case of COVID-19 pathophysiology that contributes prominently to the progression and development of disease. Therefore, targeting specific points using immunotherpeutic molecules, serious infections can be controlled or eradicated.
